SWOG Institutional Grant

描述（由申请人提供）：H。李莫菲特癌症中心是独特的定位，并准备追求其使命的治疗和预防癌症。由佛罗里达立法机构在20世纪80年代成立，成为全州范围的研究机构和国家资源的基础和临床研究和多学科的方法，病人治疗，H。李莫菲特癌症中心是唯一的NCI指定的综合癌症中心设在佛罗里达州。患者基础广泛。 科学领导力正在增长，ECOG中有81名研究者，其中许多人正在Moffitt进行药物启动的试验。癌症中心对ECOG的承诺是坚定的。它于1992年在John Ruckdeschel博士的领导下作为一个附属机构开始，很快就取得了主要成员地位，然后获得了自己的U-10资金。威廉道尔顿博士已成为H.李莫菲特癌症中心。他对合作小组机制有着深刻的承诺，将其作为研究者发起试验的一个渠道。癌症中心通过14个多学科项目发挥作用。 道尔顿博士责成每个项目负责人制定一项战略计划，其中包括各级疾病的临床试验。这将提高临床试验的收益。ECOG项目包括主要研究者Julie A. Kish，MD，协调员，Stephanie Daniels，RN，数据经理，Michele Stungis和0.5秘书职位，已成为该机构临床试验开展的典范。这扩展到莫菲特的大型附属网络，其中ECOG政策和程序指导认证，监测和教育。道尔顿博士发起了一项旨在增加少数群体参与临床试验的重大倡议，称为“解决多样性问题工作队”。因此，H. Lee Moffitt癌症中心将增加整体和少数应计费用，并教育和指导研究人员利用合作小组进行他们的临床试验。

DESCRIPTION (provided by applicant): The H. Lee Moffitt Cancer Center is uniquely positioned and prepared to pursue its mission of curing and preventing cancer. Founded by the Florida Legislature in the 1980's to become a statewide research institute and a national resource for basic and clinical research and multidisciplinary approach to patient treatment, the H. Lee Moffitt Cancer Center is the only NCI designated Comprehensive Cancer Center based in the state of Florida. The patient base is broad. The scientific leadership is growing with 81 investigators in ECOG, many of whom are doing investigator-initiated trials at Moffitt. The Cancer Center's commitment to ECOG is strong. Starting as an affiliate in 1992 under Dr. John Ruckdeschel, it soon achieved main member status and then received its own U-10 funding. Dr. William Dalton has become the new CEO of H. Lee Moffitt Cancer Center. He has a deep commitment to the cooperative group mechanism as an outlet for investigator initiated trials. The Cancer Center functions through 14 multidisciplinary programs. Each program leader has been charged by Dr. Dalton to develop a strategic plan which includes clinical trials at all levels of disease. This should enhance accrual to clinical trials. The ECOG program which includes the Principal Investigator, Julie A. Kish, MD, Coordinator, Stephanie Daniels, RN, Data Manager, Michele Stungis, and a 0.5 secretarial position, has become a model for clinical trial conduct for the institution. This extended to Moffitt's large affiliate network, where ECOG policies and procedures guide credentialing, monitoring and education. A major initiative to increase accrual of minorities to clinical trials has been instituted by Dr. Dalton called the Taskforce for Addressing Diversity (TAD). Thus, the goals of the ECOG Program at H. Lee Moffitt Cancer Center are to increase overall and minority accrual, and educate and mentor investigators to utilize the cooperative group for their investigator-initiated trials.